Prof David Thomas is the Chief Executive Officer of Omico, the Australian Genomic Cancer Medicine Centre. An NHMRC L3 Investigator, he is also the inaugural Director of the Centre for Molecular Oncology at the University of New South Wales, and Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer, particularly sarcoma. In 2019, David established Omico, which has brought together researchers and clinicians to translate research into new therapeutic options for patients with cancer. He also founded the Australasian Sarcoma Study Group, a national research organisation, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Prof Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centres in 7 countries, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. He has over 260 research publications, including lead or senior author papers in Science, Cancer Cell, Molecular Cell, Journal of Clinical Investigation, Lancet Oncology, JAMA Oncology, and Journal of Clinical Oncology. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.